Bionow supports business growth, competitiveness and innovation within the biomedical and life science sectors across Northern England. Our membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms. Our membership base includes startups and early stage firms as well as established growth-oriented companies. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.
BioPartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.
BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.
Established in 2005, Boyd provides a range of expertise and skills central to the development of pharmaceutical and biotechnology medicinal products. Boyds' consultancy services offer a cost-effective solution for those requiring expert assistance in order to expediate development, add value to products and reach key milestones.
Whether it relates to a single issue or a long-term commitment to a development team, Boyds can chart the innovative course that great science demands.
Britannia Pharmaceuticals, part of the STADA group, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease. Our key product Apomorphine Hydrochloride (Brand names: APO-go, APOKYN, Apomine) is a treatment for Parkinson’s disease which is available in many markets through our Distribution or Licensing Partners. Additionally we have developed non-opiate based therapeutics to assist in opiate detoxification and withdrawal. We are actively looking to in-license marketed products for the UK, other parts of Europe and even for the US, ideally in Movement Disorders or Mental Health but also in speciality areas where expertise is required for infusions via portable pumps. We have the infrastructure and nurse care to support the home administration of this type of product. We will also consider late stage CNS/other specialist products either in phase 3 or in registration.
Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success and enables us to provide a greater depth and breadth of services to help support your critical decision making.
Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.
What we do:
Chronos is an Oxford-based biotechnology company operating a semi-virtual R&D model to develop a portfolio of therapies in degenerative and behavioral brain diseases. The team utilises a network of industry- leading contract research organisations to develop NCEs and repurpose existing launched drugs. Chronos also has a dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™.
- Acquisition, discovery and development of novel proprietary lead candidates.
- Repositioning FDA/EMA approved drugs.
- ALS (Lou Gehrig’s Disease)
- Other Neurological Diseases
- Addictive Behaviour
Clinical Accelerator conducts all phases of clinical trials for pharma, biotech and medtech companies. We have a very simple mission: to accelerate clinical development projects and to reduce their cost appreciably for our clients. We use several strategies to achieve very compact timelines in our clinical studies: - optimization of study design (only necessary outcome measures and end-points, right number of patients, optimal follow-up duration) - selection of effective investigative sites located in our region of operation. All our sites, conducting trials to the highest standards of GCP, have a large patient recruiting capacity and a proven track record of efficient timely recruitment of qualified patients. - accelerated start up (fast regulatory and IRB/EC approval times, streamlined logistics, expedited contracting, fast site activation, USA IND or EU CTA are optional in our region of operation) - effective patient enrolment and retention (dedicated department, proven region-specific patient recruitment strategies) We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines. We routinely rescue stalled clinical trials. We are able to reduce the cost of our clinical projects significantly due to our: - flat organizational hierarchy, reasonable service rates and very modest internal overhead costs - commitment to agreed fixed budgets (rare need for change orders) - modest investigator grants and low hospital overheads in our region of operation (very large savings can be achieved in many therapeutic areas) - use of as few locations and as few investigative sites as possible without compromising patient recruitment rates (this limits set-up costs and lowers per patient cost) - short study timelines, which lead to reduced management costs - potential risk sharing (optional strategy) The cost of our studies is among the most attractive globally. We commit to our budgets and fix them for our clients.
Clinical Network Services (CNS)
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Colibri Scientific provides fast and flexible clinical sample operational services to clinical investigators, biotechnology and pharmaceutical companies running small to medium scale multi-centre studies. Our team is made up of industry experts with many years’ experience in the field.
As our name suggests (Colibri – hummingbird), we are a small, agile and efficient company which offers a fully customisable service to meet the needs of our clients; something that is difficult to achieve from larger organisations. We aim to deliver the specific sample requirements of your trial, regardless how small, using a flexible approach together with scientific rigour and organisational expertise.
Colliers International Group Inc. (NASDAQ and TSX: CIGI) is an industry-leading global real estate services company with 15,000 skilled professionals operating in 68 countries. Our services include strategic advice and execution for property sales, leasing and finance; global corporate solutions; property, facility and project management; workplace solutions; appraisal, valuation and tax consulting; customized research and thought leadership consulting.